Showing 5341-5350 of 5621 results for "".
- FDA Commissioner Gottlieb Announces Efforts to Improve Assessment of REMS Programshttps://modernod.com/news/fda-commissioner-gottlieb-announces-efforts-to-improve-assessment-of-rems-programs/2479604/In an FDA statement, Commissioner Scott Gottlieb, MD, announced efforts to improve the quality of the information used to assess the effectiveness of Risk Evaluation and Mitigation Strategy (REMS) programs in supporting the safe use of medications. In making decisions about whether the ben
- Cultivating 4-D Tissues: The Self-Curving Corneahttps://modernod.com/news/cultivating-4-d-tissues-the-self-curving-cornea/2476176/Scientists at Newcastle University have developed a biological system which lets cells form a desired shape by moulding their surrounding material—in the first instance creating a self-curving cornea. In the research, a flat circle of gel containing corneal stromal cells (stem
- Compulink Showcases SMART Ophthalmology EHR Solution at Hawaiian Eye 2019https://modernod.com/news/compulink-showcases-smart-ophthalmology-ehr-solution-at-hawaiian-eye-2019/2476177/Compulink Healthcare Solutions will demonstrate its ophthalmology-specific system, Ophthalmology Advantage at Hawaiian Eye. Ophthalmology Advantage uses AI technology and real-time data from the clinic to completely automate tasks such as billing, along with eliminating steps to improve pa
- DORC Unveils Enhancements to the EVA Phacovitrectomy Systemhttps://modernod.com/news/dorc-unveils-enhancements-to-the-eva-phacovitrectomy-system/2476178/DORC has announced the launch several enhancements to its EVA surgical system aimed at delivering both operating room efficiency and surgical performance. The enhancements include a new EVA footswitch that been completely redesigned. Control of the EVA endolaser is now integrated into the
- Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-completes-patient-dosing-in-time-2b-study-of-akb-9778-in-diabetic-retinopathy/2476181/Aerpio Pharmaceuticals announced the completion of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe nonproliferative diabetic retinopathy (NPDR). &#
- Cyclosporine Emulsion Promising in Vernal Keratoconjunctivitishttps://modernod.com/news/cyclosporine-emulsion-promising-in-vernal-keratoconjunctivitis/2476182/Cyclosporine A cationic emulsion (CsA CE) appears more effective than vehicle alone in treating pediatric patients with vernal keratoconjunctivitis, according to a study funded by the developer, Santen, as reported by Reuters. In a
- MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF for Ophthalmic Diseaseshttps://modernod.com/news/manf-therapeutics-receives-notice-of-allowance-from-us-patent-trademark-office-covering-the-use-of-manf-or-cdnf-for-ophthalmic-diseases/2476184/MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, is in preclinical development advancing mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions and neurodegenerative diseases. On Tuesday, the
- FDA to Boost Staff to Help Handle Anticipated Increase in Cell and Gene Therapy Filingshttps://modernod.com/news/fda-to-boost-staff-to-help-handle-anticipated-increase-in-cell-and-gene-therapy-filings/2476185/FDA Commissioner Scott Gottlieb said Tuesday that the agency’s “eventual goal” is to add about 50 additional clinical reviewers to the group that oversees the clinical investigation, development, and review of cell and gene therapy products. He also cited the more than 800 activ
- Acuity Pro Launches Acuity Ten Digital Software and Systemhttps://modernod.com/news/acuity-pro-launches-acuity-ten-digital-software-and-system/2476187/The new Acuity Pro Ten digital visual acuity system is built with future-proofing in mind. Written in a new language, the program looks and feels very familiar with user-interface enhancements designed for ease-of-use, according to a company news release. To keep up with Windows updates and the r
- Analysts Believe M&A Activity in the Pharmaceutical Sector Could Rise in 2019https://modernod.com/news/analysts-believe-ma-activity-in-the-pharmaceutical-sector-could-rise-in-2019/2476194/Analysts and investors hinted that M&A activity among drugmakers could increase in 2019 compared to the prior year, Business Insider reported